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Feasibility and safety of mass drug coadministration with 
azithromycin and ivermectin for the control of neglected 
tropical diseases: a single-arm intervention trial
Lucia Romani, Michael Marks, Oliver Sokana, Titus Nasi, Bakaai Kamoriki, Handan Wand, Margot J Whitfeld, Daniel Engelman, 
Anthony W Solomon, Andrew C Steer, John M Kaldor
Summary
Background Mass drug administration has made a major contribution to the public health control of several important 
neglected tropical diseases. For settings with more than one endemic disease, combined mass drug administration 
has potential practical advantages compared with separate programmes but needs confirmation of feasibility and 
safety. We undertook a study of mass drug administration in the Solomon Islands for trachoma and scabies control 
using ivermectin and azithromycin, key drugs in the control of neglected tropical diseases worldwide.
Methods The entire population of Choiseul province, Solomon Islands, was eligible to participate. An azithromycin-
based mass drug administration regimen was offered in line with standard recommendations for trachoma 
elimination (oral azithromycin or topical tetracycline). An ivermectin-based mass drug administration regimen was 
offered at the same time (oral ivermectin or topical permethrin), with a further dose 7–14 days later, using a modified 
version of a regimen demonstrated to be effective for scabies control. All participants underwent safety assessments 
7–14 days later. Participants in ten randomly selected sentinel villages underwent a more detailed safety assessment. 
Routine health system reports of hospital or clinic admissions and deaths were also obtained to compare health 
outcomes in the 12 month period before and after the mass drug administration.
Findings The study enrolled 26 188 participants, 99·3% of the estimated resident population as determined at the 
2009 census. Of those enrolled, 25 717 (98·2%) received the trachoma regimen and 25 819 (98·6%) received the first 
dose of the scabies regimen between Sept 1, and Oct 2, 2015. A second dose of the scabies regimen was received by 
21 931 (83·7%) of participants. Adverse events, all mild and transient, were recorded in 571 (2·6%) of the entire study 
population and 58 (4·1%) of participants in the ten sentinel villages. In the 12 months before and after the mass drug 
administration the numbers of hospital admissions (1530 vs 1602) and deaths (73 vs 83) were similar. In the month 
after the mass drug administration, 84 individuals were admitted to hospital and two died, compared with a monthly 
median of 116 admissions (IQR 106–159) and six deaths (IQR 4–7) in the 12 months before and after the mass drug 
administration.
Interpretation In the largest trial so far involving coadministration of regimens based on ivermectin and azithromycin, 
the combination was safe and feasible in a population of more than 26 000 people. Coadministration of mass drug 
administration based on these two drugs opens up new potential for the control of neglected tropical diseases.
Funding International Trachoma Initiative, Murdoch Children’s Research Institute, Scobie and Claire Mackinnon 
Trust, Wellcome Trust.
Copyright ©2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Mass drug administration involves treatment of whole 
populations with a pharmaceutical agent to reduce or 
interrupt transmission of an infectious pathogen. It has 
become a key strategy for the control of neglected tropical 
diseases in several low-income and middle-income 
countries.1 The five main neglected tropical diseases 
currently targeted by mass drug administration are 
oncho cerciasis, lymphatic filariasis, trachoma, schisto-
somiasis, and infection with soil-transmitted helminths, 
diseases that are strongly related to living conditions and 
primarily affect rural populations in resource-limited 
settings.2,3 Mass drug administration is intended to 
complement improvements in both environmental risk 
factors and health service access, to ultimately achieve 
elimination of these diseases.4
Many communities are affected by multiple neglected 
tropical diseases.5,6 Although some programmes for mass 
drug administration target more than one neglected 
tropical disease (eg, combined ivermectin and albendazole 
for both lymphatic filariasis and onchocerciasis), they are 
more often aimed at single diseases. There has been 
increasing international recognition of the need to better 
integrate these vertical structures, both with each other, 
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and with local health systems.7–10 The potential logistical 
and health benefits of integration include cost savings, 
reduced burden on health systems and communities, 
and better disease control through improved coverage. 
However, uncertainties remain about the feasibility 
of integration in resource-limited settings, and about 
the efficacy and safety of coadministration of drugs on a 
large scale.1,7,11
Azithromycin is an antibacterial drug that has 
been used in mass drug administration for trachoma 
elimination as part of the Surgery, Antibiotics, Facial 
Cleanliness & Environmental Improvement (SAFE) 
strategy for nearly 20 years.12 It is also effective against 
yaws and is recommended by WHO for this indication.13–15 
Ivermectin is an antiparasitic drug that has been 
widely used for mass drug administration for lymphatic 
filariasis and onchocerciasis, and is also effective as 
mass drug administration for scabies, a newly designated 
neglected tropical disease.9,16–18 With trachoma (and yaws) 
coendemic with combinations of lymphatic filariasis, 
onchocerciasis, and scabies in several countries, the joint 
use of azithromycin and ivermectin (with or without 
albendazole) might be an effective approach to improve 
coverage and integration of these programmes.19 Previous 
small pharmacokinetic studies of the joint administration 
of combinations of azithromycin, ivermectin, and 
albendazole in healthy volunteers have shown very few 
interactions.19,20 The only previous published trial of the 
combination of ivermectin and azithromycin (plus 
albendazole) in the setting of a neglected tropical disease 
involved 1500 people in Mali and found mild, transitory 
adverse events consistent with the known profiles of the 
individual drugs when used alone, and no evidence of 
potentiation.21 Although promising, the study provided 
insufficient power to detect rare adverse events arising 
from coadministration and highlighted the need for 
large field studies of this strategy.
The Solomon Islands has high levels of both trachoma22,23 
and scabies.24,25 On the basis of WHO SAFE strategy guide-
lines, mass administration of azithromycin for trachoma 
was implemented by the Ministry of Health and Medical 
Services across all ten provinces from 2014 to 2015.22,26,27 
With emerging data on the effectiveness of ivermectin 
mass administration for scabies control,17 we did a trial 
which aimed to address outstanding questions on the 
feasibility and safety of large-scale coadministration of 
regimens based on ivermectin and azithromycin in 
Choiseul Province, the last province scheduled to receive 
mass drug administration for trachoma.
Methods
Study design and participants
The Azithromycin Ivermectin Mass Drug Administration 
(AIM) study was a prospective, single-arm, before-and-
after community intervention trial to assess the feasibility 
and safety of joint mass drug administration with 
ivermectin and azithromycin for trachoma and scabies 
control in a large population in the Solomon Islands.
The study was done in Choiseul Province of the 
Solomon Islands, an island nation in the South Pacific 
region with a population of approximately 580 000 people 
across roughly 990 islands.28 Choiseul is located in the 
Research in context
Evidence before this study
We searched PubMed, Ovid Medline, and Embase, without 
language restrictions, for studies reporting on the mass 
coadministration of azithromycin-based and ivermectin-based 
regimens, published up to Nov 15, 2017, with the terms 
“azithromycin” and “ivermectin”. We identified one study of 
1500 participants in a setting of endemic neglected tropical 
disease, showing that this combination (plus albendazole) 
resulted in mild, transitory adverse events consistent with the 
known profiles of the individual drugs when used alone, and 
no evidence of potentiation. This study, however, provided 
insufficient power to detect uncommon adverse events arising 
from coadministration and highlighted the need for large field 
studies of this strategy. Additionally, it did not investigate 
coverage and feasibility issues of coadministration of these 
two therapies.
Added value of this study
Our trial was designed to investigate the feasibility and safety 
of mass drug administration of two integrated therapies with 
azithromycin and ivermectin. To our knowledge, it is the first 
published large-scale trial of coadministration of this strategy 
to control neglected tropical diseases, providing safety 
information on more than 26 000 people as opposed to 1500 in 
the only previous study. In our study, safety was evaluated 
using active and passive monitoring of adverse events as well as 
a comprehensive review of routine clinic and hospital 
admission records for the 12 months before and after the 
intervention. We investigated the feasibility of joint mass 
administration of the two regimens, demonstrating that 
coadministration based on these two drugs opens up new 
potential for the control of neglected tropical diseases.
Implications of all the available evidence
The study provides evidence that coadministration of 
azithromycin and ivermectin is feasible and safe in a population 
of more than 26 000 people in a neglected tropical 
disease-endemic setting. We have demonstrated that a high 
level of population coverage is achievable in a large and 
geographically disperse population and provided robust 
evidence of the safety of this strategy in population settings. 
Our findings, therefore, support the strategy of integration of 
mass drug administration for neglected tropical diseases 
sharing similar target populations and therapies to reduce costs 
and allow a more rapid scale-up of programmes. 
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northwest of the country. Health care in Choiseul in 2015 
was provided by 17 nurse aid posts, 10 rural health clinics, 
one area health centre, and a hospital located in Taro, the 
provincial capital.29
All Choiseul residents were eligible to participate. At 
the 2009 national census, the population of Choiseul 
was 26 372.28 The Solomon Islands National Statistics 
Office projected the population to be 32 548 in 2015, using 
an estimated annual increase in national population of 
approximately 2·5% per year, based on mortality, fertility, 
and migration rates.30 The projected figures are probably 
overestimates because they do not account for either 
migration to the national capital and other urban areas 
for school or employment, or a reported reduction in 
birth rates in Choiseul in recent years.31,32
The study was approved by the Solomon Islands 
National Research Ethics Committee (15/33) and the 
Royal Children’s Hospital Human Research Ethics 
Committee (35148A). The ethics committees approved 
the use of oral consent for joint administration in this 
study. Participants who were asked to undertake a skin 
examination provided written consent. 
Procedures
Drugs were delivered by Ministry teams using the 
procedures of the national trachoma programme, but 
incorporating an additional visit after 1 week to deliver the 
second dose of the ivermectin-based regimen for scabies 
control. All team members received training on study 
activities before the trial commencement. We obtained 
verbal consent, in local dialect, for individuals aged 18 years 
or older and verbal consent from a parent or guardian for 
younger individuals. Before drug administration, infor-
mation sheets explaining the trial were distributed to local 
community nurses who were trained in study procedures, 
and community members were given an opportunity 
to meet the local health staff to ask questions. Apart 
from the study-specific consent process, community 
mobilisation efforts were identical to those that had been 
used by the Ministry of Health in preparing other provinces 
for trachoma-related mass administration of azithromycin. 
Individuals who consented to receive the regimen were 
asked to attend the village clinic or community hall to 
receive treatment on an agreed date.
Interventions
The azithromycin regimen for trachoma followed WHO 
guidelines, identical to that used for trachoma mass drug 
administration in the rest of the country.22 Participants 
were offered a single oral dose of azithromycin at a dose 
of 20 mg/kg, using weight bands (appendix), up to a 
maximum of 1 g. Children weighing less than 12·5 kg 
received oral suspension at a dose of 20 mg/kg; others 
received tablets. Infants younger than 6 months were not 
given azithromycin, but instead were offered topical 
tetracycline ointment 1% for administration by a parent 
or guardian to both eyes twice per day for 6 weeks.
For administration of ivermectin for scabies, participants 
were offered a dose of oral ivermectin at 200 µg/kg, using 
weight bands, at the same time as the trachoma drug 
administration. The same dose was offered a second time, 
7–14 days later. This regimen was based on a protocol 
shown to be safe and effective in a previous trial,17 with 
the modification that the second dose was offered to 
all participants (rather than being restricted to those 
with clinical scabies at baseline) because clinical examin-
ation of all participants was infeasible on such a large 
scale. Pregnant and breastfeeding women and children 
weighing less than 12·5 kg were offered two applications 
of topical permethrin cream 7–14 days apart, rather than 
ivermectin. We used 12·5 kg as the lower limit (rather 
than 15 kg, which is used for weight-based dosing of 
ivermectin in mass administration for lymphatic filariasis 
and onchocerciasis), to make administration consistent 
with the azithromycin weight cutoff.
Oral drug administration was directly observed for 
both ivermectin and azithromycin. Participants offered 
permethrin were given the option to apply the cream at 
home, or to have a trained nurse apply it in a private 
room at the clinic. For topical therapies (tetracycline and 
permethrin), appropriate use of the medication was 
explained on a one-to-one basis by a member of the study 
team to the recipient, or the recipient’s carer.
Outcomes
The coverage of mass drug administration regimens for 
scabies and trachoma, and of coadministration for both 
diseases, was calculated using the 2009 census data as 
the denominator, with subanalysis by age and weight 
bands. Coadministration was deemed successful if 
the coverage for both diseases was similar to that 
for trachoma achieved by other provinces in the same 
campaign (approximately 80%). For comparison with 
single-agent regimens, we obtained programmatic 
coverage data from other provinces in which the Ministry 
of Health had previously conducted mass administration 
of azithromycin for trachoma.
Safety was evaluated via four methods, incorporating 
standard definitions of adverse events.33 First, we sought 
information on the occurrence of immediate severe 
adverse events, defined as admission to hospital or death 
within 24 h of exposure to study medicine, as recorded in 
hospital records and a review of death reports. Second, we 
asked all participants about their current health (“Are you 
well today?”) at the time of initial drug administration. At 
the time of the second dose of the ivermectin-based 
scabies regimen participants were asked about their 
health status since the first dose (“Have you had any 
problem with the first dose?”). If they answered in the 
negative, we administered a checklist of health conditions, 
supplemented by free text recording of conditions not on 
the checklist. Third, we undertook active surveillance for 
adverse events in ten randomly selected sentinel villages. 
In these communities, we administered a questionnaire 
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at both occasions of drug administration which sought 
information on the presence or absence of each condition 
on the checklist, again using a free text field to elicit 
conditions not on the list. Finally, we undertook a review 
of routine clinic and hospital admission records submitted 
through the national District Health Information System 
(DHIS2) during the 12 months after mass drug admini-
stration, and compared those data to data for the 12 months 
before mass drug administration.
Statistical analysis
Participant characteristics were summarised by demo- 
graphic categories (age, sex, and health zone) and 
compared with the distribution of these characteristics in 
the 2009 national census. We calculated coverage by 
age group and sex, separately for the azithromycin 
administration, the first dose of the ivermectin adminis- 
tration, both doses of the ivermectin administration, and 
for the full combination. All statistical analyses were 
done with STATA 14.0.
The trial is registered with the Australian and New 
Zealand Trials Registry, number ACTRN12613000474752.
Results
26 188 people consented to participate in the study, 
representing 99·3% of the resident population based on 
the 2009 census (26 372 individuals), and 80·5% based 
on the 2015 projected population (32 548 individuals). 
The demographic features of enrolled participants were 
similar to those reported in the census (table 1). Delivery 
of mass drug administration began on Sept 1, 2015, and 
was completed by Oct 2, 2015.
Of the enrolled population, 25 488 (97·3%) received the 
trachoma regimen and the first dose of the scabies 
regimen, including 21 181 (83·1%) who received both 
ivermectin and azithromycin at this first visit as part of 
these regimens. Almost all participants treated with the 
trachoma regimen received azithromycin (25 278 [98·3%] 
individuals), whereas 16·9% of participants who received 
the scabies regimen received permethrin rather than 
ivermectin (table 2). 21 817 (85·6%) participants received 
the trachoma regimen and both doses of the scabies 
regimen. 40 (0·2%) participants were not recorded as 
having received either regimen, and 560 (2·1%) received 
only one (229 [0·9%] received only treatment for 
trachoma and 331 [1·3%] received only treatment for 
scabies). Specific data on why these 560 individuals 
did not receive both treatments at the first visit was 
not available.
There were no immediate serious adverse events 
reported. Of 21 817 participants who responded to the 
question on current health at the time of the second visit, 
571 participants (2·62%) reported 655 adverse events 
since the first visit (table 3), all of which were mild 
and resolved within 1 week following treatment. Most 
commonly reported were dizziness (144 individuals, 
0·7%), abdominal pain (80, 0·4%), and diarrhoea 
(71, 0·3%). 46 participants reported more than one event.
Adverse events were more common in older partici-
pants (table 4). Seven children (0·2%) younger than 
5 years who received ivermectin experienced adverse 
events. Of 1293 children weighing 12·5–15 kg who 
received ivermectin, seven (0·5%) experienced an 
adverse event. Adverse events were more frequently 
reported by the 21 181 participants who received azithro-
mycin and ivermectin (513, 2·4%) compared with the 
4375 who received azithromycin and permethrin (57, 
1·2%, p<0·0001).
In the ten sentinel villages with more detailed safety 
monitoring, 1399 participants were enrolled (94·6% of 
the registered resident population of 1479 individuals). 
Adverse events were reported by 58 (4·1%) participants 
Study population 
(n=26 188)
Census 2009 
(n=26 372)
Sex 
Male 13 259 (50·6%) 13 532 (51·3%)
Female 12 809 (48·9%) 12 840 (48·7%)
Missing 120 (0·5%) ··
Age
0–4 years 3856 (14·7%) 4035 (15·3%)
5–9 years 3881 (14·8%) 3842 (14·6%)
10–14 years 3633 (13·9%) 3262 (12·4%)
15–24 years 4262 (16·3%) 4499 (17·2%)
25–34 years 3419 (13·1%) 3783 (14·3%)
≥35 years 7137 (27·3%) 6951 (26·4%)
Zone
South 9225 (35·2%) 8435 (32·0%)
Northeast 5261 (20·1%) 5982 (22·7%)
Northwest 11 702 (44·7%) 11 955 (45·3%)
Table 1: Demographic characteristics of study participants
Number receiving 
treatment (n=26 188)
Scabies regimen first dose 25 819 (98·6%)
Oral ivermectin 21 444 (83·1%)
Topical permethrin 4375 (16·9%)
Scabies regimen second dose 21 931 (83·7%)
Oral ivermectin 18 215 (83·1%)
Topical permethrin 3716 (16·9%)
Trachoma regimen 25 717 (98·2%)
Oral azithromycin 25 278 (98·3%)
Topical tetracycline 439 (1·7%)
Combination scabies and trachoma regimen 
(first dose for scabies)
25 488 (97·3%)
Coadministration of ivermectin (first dose) 
and azithromycin
21 181 (83·1%)
Combination scabies and trachoma 
regimen (both doses for scabies)
21 817 (85·6%)
Table 2: Coverage of mass drug administration regimens for scabies and 
trachoma
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in these villages, all mild and transient (table 3), with the 
most being itch (12 individuals, 0·9%), diarrhoea 
(ten, 0·7%), and headache (ten, 0·7%).
In the 12 months leading up to the intervention 
(September, 2014, to August, 2015, inclusive) there were 
1530 hospital admissions and 70 deaths. In the 12 months 
after (October, 2015, to September, 2016, inclusive) there 
were 1602 admissions and 75 deaths (appendix). The 
median number of admissions for the entire 25 month 
period was 116 (IQR 106–159) and the median number of 
deaths was six (IQR 4–7). In October, 2015, there were 
84 admissions and two deaths compared to five deaths 
each in September and November of the same year, 
respectively. These numbers did not seem to differ 
between the periods before and after the intervention.
Discussion
To our knowledge, this trial is the first published report 
of large-scale coadministration of ivermectin and azithro-
mycin as components of neglected tropical disease 
control. We have demonstrated that coadministration of 
the two drugs was safe and feasible. The lack of any 
serious adverse events in a population of more than 
21 000 people, and the small number of adverse events, 
indicate that coadministration is a viable means of 
integrating programmes to control multiple, coendemic 
neglected tropical diseases. Furthermore, the high level 
of coverage achieved, both for the coadministration 
and the second dose of the ivermectin-based scabies 
regimen, indicates the feasibility of coadministration as 
strategy for mass drug administration. A randomised trial 
might have provided more detailed data on safety, but 
would not have been feasible on this scale, due to costs 
and the burden that would have been imposed on the 
Solomon Islands health system.
Although the benefit of mass azithromycin admini-
stration for trachoma is well established,34 the evidence 
for benefit of mass administration of ivermectin-based 
regimens for scabies control has emerged only recently, 
most notably in the SHIFT study, the strategy’s first 
comparative trial.17,24,35–39 SHIFT took place in Fiji and 
its findings showed that a single round of mass 
drug administration with ivermectin reduced community 
prevalence of scabies by 94% at 1 year, a substantially 
greater reduction than either mass permethrin admini-
stration or standard care.17 In the present study, we 
have shown that a high level of population coverage can 
be achieved in a large and geographically dispersed 
population, even when including a second dose of 
ivermectin for the entire population. Coverage levels for 
the first dose (which involved joint administration of the 
two regimens) was similar to levels achieved for mass 
azithromycin administration alone in the other Solomon 
Islands provinces (86% in 2014–15, Oliver Sokana, 
personal communication). Given the high costs of trans-
port and other logistics in remote settings, joint delivery 
of two drugs in mass administration regimens has the 
potential to deliver considerable savings. However, a 
specific difficulty with the current ivermectin-based 
regimen for scabies is the requirement of a second 
dose after 7–14 days, to kill newly hatched mites;40 
this regimen is distinct from the schedules used for 
mass ivermectin administration for lymphatic filariasis 
and onchocerciasis, which require only a single dose. 
Although we achieved high coverage with the second 
dose, the logistical challenges and increased cost 
clearly represent a potential barrier to the wider use of 
ivermectin for scabies control and to routine integration 
with other neglected tropical disease programmes. 
Further studies of the efficacy of one instead of two doses 
for scabies, or longer-acting drugs such as moxidectin,41 
might widen the possibilities for the integration of mass 
drug administration for scabies with other neglected 
tropical disease programmes without entailing the 
additional costs of delivering the second dose.
Adverse events 
overall (n=21 817)
Adverse events in 
ten sentinel villages 
(n=1399)
Dizziness 144 (0·7%) 6 (0·4%)
Abdominal pain 80 (0·4%) 8 (0·6%)
Diarrhoea 71 (0·3%) 10 (0·7%)
Headache 47 (0·2%) 10 (0·7%)
Muscle pain 42 (0·2%) 4 (0·3%)
Joint pain 37 (0·2%) 5 (0·4%)
Itch 24 (0·1%) 12 (0·9%)
Nausea 15 (0·1%) 3 (0·2%)
Vomiting 6 (<0·1%) 0
Other* 59 (0·3%) 0
Individuals who experienced 
more than one event
46 (0·2%) 0
Individuals who experienced 
at least one event
571 (2·6%) 58 (4·1%)
Adverse event data were collected at the second study visit 7–14 days after the 
baseline coadministration of azithromycin and ivermectin. *Other reported events 
included skin conditions (n=29, including 15 tinea infections and seven molluscum 
contagiosum), eye conditions (n=17), and other miscellaneous (n=13, including 
conditions such as broken knee).
Table 3: Adverse events reported by participants
Participants who 
received 
coadministration 
(n=21 817)
Participants with 
adverse events 
(n=571)
0–4 years 3693 22 (0·6%)
5–9 years 3820 38 (1·0%)
10–14 years 3582 54 (1·5%)
15–24 years 4179 107 (2·6%)
25–34 years 3298 118 (3·6%)
≥35 years 6916 232 (3·4%)
Table 4: Participants with adverse events by age group among those 
who received coadministration
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In the largest previous study, with 1500 people receiving 
the combination, there was no indication of clinically 
significant adverse events or alterations in efficacy.21 Our 
findings in a much larger population provide more 
robust evidence for the safety of coadministration of 
ivermectin and azithromycin in population settings. Our 
study also provides encouraging data on the safety of 
ivermectin in younger children, particularly those 
weighing as little as 12·5 kg. Gastrointestinal upset, 
headache, and dizziness are well recognised side-effects 
of azithromycin and ivermectin and were the most 
commonly encountered adverse events in this study, all 
of a mild nature.
Our study had some limitations. The design was non-
randomised, so safety assessments relied on before-and-
after comparisons in the same population. We also 
adopted a pragmatic means to assess safety across the 
target population. For the entire population of 
26 188 participants, we sought open-ended information 
on health status at the time of coadministration, and 
again at the time of delivery of the second dose of the 
scabies regimen, 7–14 days after the two drugs had been 
received. We also sought more detailed symptom-
specific information on about 6% of participants resident 
in the ten sentinel villages. However, we were not able to 
assess safety in this manner for the 3888 (16·3%) 
participants who did not receive the second dose. Also, 
we might have missed mild, transient adverse events 
that occurred within a short time of joint administration 
but had been forgotten by participants by the time they 
were interviewed at the second dose. We supplemented 
this active surveillance approach with routinely recorded 
data on hospital admissions and deaths in the periods 
preceding and following mass drug administration. The 
absence of any signal of increased health-care use after 
mass drug administration is consistent with our active 
surveillance data.
The integration of mass drug administration for 
neglected tropical diseases sharing similar target 
populations and drug regimens, as demonstrated in our 
study, has the potential to facilitate medication delivery, 
thereby reducing costs and allowing more rapid scale-
up of programmes for multiple neglected tropical 
diseases. The evidence from our trial is that, on a very 
large scale, there were not serious adverse events arising 
from the joint administration of the two regimens. 
Studies in different populations, including different 
combinations of drugs (eg, triple therapy with 
ivermectin, albendazole, and azithromycin), are needed 
to further expand the evidence base for coadministration 
as a global strategy for control and elimination of 
neglected tropical diseases.
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